News Releases 2013

RSS

27 DEC 2013 Pharmaceuticals
European Medicines Agency (EMA) Accepts Otsuka's Marketing Authorisation Application (MAA) for Tolvaptan, an Investigational Compound for Autosomal Dominant Polycystic Kidney Disease (ADPKD)
11 DEC 2013 Pharmaceuticals
Lundbeck and Otsuka to Co-Develop a Vaccine, Lu AF20513, Their Third Collaborative Development Project to Tackle Alzheimer’s Disease
3 DEC 2013 Corporate
Providing Free Health Care to Over 700,000 Afghan Refugees :
The 10th Anniversary of the “Otsuka Welfare Clinic”
25 NOV 2013 Pharmaceuticals
CHMP Recommends Otsuka’s Deltyba™ (delamanid) for EU Approval for Treatment of Multidrug-Resistant Tuberculosis (MDR-TB) in Combination with Optimized Background Regimen (OBR)
25 NOV 2013 Nutraceuticals
New From the US, A Smart New Way to Take Vitamin and Mineral Supplements VitaMelts® Dissolve Smoothly Without Water
Available at Convenience Stores Throughout Japan From November 25
21 NOV 2013 Pharmaceuticals
Otsuka and Lundbeck's Once-Monthly
Abilify Maintena® (Aripiprazole) Now Approved in Europe for Maintenance Treatment of Schizophrenia in Adult Patients Stabilized with Oral Aripiprazole
5 NOV 2013 Corporate
Otsuka Co-sponsors the Fifth Annual Asan Walking Festival in Itano on November 10
31 OCT 2013 Pharmaceuticals
Otsuka Named as Lundbeck’s Partner in Japan on Nalmefene for the Reduction of Alcohol Consumption
23 OCT 2013 Nutraceuticals
Get the Dietary Fiber That is Missing From Your Diet With a Healthy Combination of Cereal Grains
Otsuka Launches the New Products “Gerble Multicereal Chocolate” and “Gerble Multicereal Apricot

Go to the Top

10 OCT 2013 Pharmaceuticals
Lundbeck and Otsuka Initiate Phase III Clinical Trials on Lu AE58054 as a New Add-On Treatment for Alzheimer's Disease
1 OCT 2013 Pharmaceuticals
Otsuka Pharmaceutical Receives the 2013 Good Design Award for the Antiplatelet Drug “Pletaal® OD Tablets”
20 SEP 2013 Pharmaceuticals
Otsuka And Lundbeck Receive Postive Chmp Opinion In Europe For Abilify MaintenaTM, A Once-Monthly Injectable For Schizophrenia
18 SEP 2013 Nutraceuticals
Two New Flavors of SoyCarat Nori & Natto and Olive Oil & Garlic Flavors Debut October 2
17 SEP 2013 Pharmaceuticals
Vasopressin V2 Receptor Antagonist Samsca®7.5mg Tablets Granted Additional Indication in Japan for the Treatment of Fluid Retention in Patients with Hepatic Cirrhosis
5 SEP 2013 Corporate
Otsuka Pharmaceutical to Acquire Astex Pharmaceuticals
5 SEP 2013 Nutraceuticals
UL•OS Line of Men’s Skin Care Marks 5th Anniversary
Now Effective in Minimizing the Appearance of Fine Lines and Wrinkles Caused by Dryness
30 AUG 2013 Pharmaceuticals
Otsuka Receives Complete Response Letter From U.S. Food And Drug Administration For Tolvaptan For Use In Patients With Autosomal Dominant Polycystic Kidney Disease
28 AUG 2013 Pharmaceuticals
Japan’s First Dry Syrup Formulation of an Anti-epileptic Drug for the Treatment of Partial-onset Seizures, E Keppra® Dry Syrup 50%, to Be Launched on August 29
19 AUG 2013 Nutraceuticals
On September 1, Otsuka Launches “Omugi Seikatsu,”
a Healthy Breakfast Food With Barley Beta-Glucans

Go to the Top

6 AUG 2013 Pharmaceuticals
U.S. Food and Drug Administration's Cardiovascular and Renal Drugs Advisory Committee Recommends Against Approval of Otsuka Pharmaceutical's Tolvaptan for Use in Autosomal Dominant Polycystic Kidney Disease (ADPKD)
6 AUG 2013 Pharmaceuticals
Fingraph®, a fingertip blood sampler that conveniently measures sodium and potassium electrolyes in just one minute, debuts in Japan on August 6
1 AUG 2013 Corporate
Come Check Out Our Brand New English Site! Global Website for Global Company Launches on Aug 1, 2013 http://www.otsuka.co.jp/en
26 JUL 2013 Pharmaceuticals
Otsuka Receives Opinion from CHMP on Delamanid
17 JUL 2013 Pharmaceuticals
Phase II clinical data show statistically significant improvement for Lu AE58054 as add-on to donepezil, versus donepezil alone, on cognitive symptoms of Alzheimer’s disease Lundbeck and Otsuka present data at Alzheimer’s Association International Conference 2013
10 JUL 2013 Nutraceuticals
A Heat Wave Is Coming – Protect Yourself From Heat Stroke Otsuka’s New “Heat Stroke Prevention Information” Service Launches July 8, Receive Automatic Updates on a “Heat Index” Indicating Your Heat Stroke Risk Level
10 JUL 2013 Pharmaceuticals
Otsuka Europe Development and Commercialisation Ltd., a New Company for the Development of Pharmaceuticals Opens in the UK
28 JUN 2013 Pharmaceuticals
Two New Formulations of E KeppraR Developed Dry Syrup Obtains Approval; Application Filed for Injectable Formulation, Address various needs of patients with epilepsy from 4 years of age and contribute to improvement of compliance with medication
14 JUN 2013 Pharmaceuticals
A New Choice of Therapy for the Treatment of Depression: ABILIFY® Granted Additional Approval as Adjunctive Therapy for the Treatment of Depression in Japan
10 JUN 2013 Nutraceuticals
The No.1 pharmacist-recommended supplement「Nature Made」, The First Supplement Facility was Built in Alabama, Production Capacity Increases 40% by 2014

Go to the Top

7 JUN 2013 Corporate
Otsuka has been selected by METI, as a model enterprise for business continuity management
3 JUN 2013 Pharmaceuticals
Otsuka Pharmaceutical Submits New Drug Application in Japan for Tolvaptan for the Treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD)
3 JUN 2013 Pharmaceuticals
Vasopressin V2 Receptor Antagonist Samsca® 7.5mg Tablets To Be Launched in Japan on June 4 – Additional Choice of Dose for the Treatment of Volume Overload in Patients with Heart Failure
31 MAY 2013 Pharmaceuticals
Antiepileptic Drug E Keppra® Tablet Approved in Japan for Pediatric Epilepsy (Partial-Onset Seizures)
22 MAY 2013 Pharmaceuticals
Study Shows Effects of Treatment with ABILIFY MAINTENA(Aripiprazole) on Psychiatric Hospitalization Rates for Patients with Schizophrenia
9 MAY 2013 Pharmaceuticals
Acucela and Otsuka Pharmaceutical Announce Phase IIa Clinical Results of Emixustat Hydrochloride (ACU-4429) in Patients with Geographic Atrophy (GA) Associated with Dry Age-related Macular Degeneration (AMD) at ARVO 2013 Annual Meeting
30 APR 2013 Pharmaceuticals
Otsuka Pharmaceutical’s 44-member Employee Dance Group “Otsuka-Ren”
Presented Traditional “Awa-Odori” of Tokushima, Where the Company Originates From,
At Copenhagen Sakura Festival Held in Denmark
17 APR 2013 Pharmaceuticals
“Epi Diary”– An Epilepsy Diary Application for iOS
A New Communication Tool for Patients with Epilepsy and their Physicians
Now Available at https://itunes.apple.com/app/epi-diary/id616736809?Is=1&mt=8
12 APR 2013 Pharmaceuticals
Otsuka’s New Drug Application For Tolvaptan, An Investigational Compound For Autosomal Dominant Polycystic Kidney Disease (ADPKD), Accepted For Review By The US Food And Drug Administration (FDA)
4 APR 2013 Nutraceuticals
New Version of POCARI SWEAT
Low calorie beverage with subtle sweetness, refreshing after-taste
POCARI SWEAT ION WATER, Debuts April 8, 2013

Go to the Top

1 APR 2013 Corporate
Like Having Everything At Your Fingertips? Then Check This Out!
Otsuka Pharmaceutical Announces A Revamped Website, April 1, 2013
http://www.otsuka.co.jp/
27 MAR 2013 Pharmaceuticals
Otsuka’s Novel Treatment for Multidrug-Resistant Tuberculosis, Delamanid,
Submitted For Regulatory Approval in Japan -- Half Century Since Last Drug Was Approved in Japan for Tuberculosis
26 MAR 2013 Pharmaceuticals
Lundbeck and Otsuka Further Expand Alliance and Enter Into Collaboration For the Development and Commercialization of Lu AE58054 In Development For Alzheimer’s Disease
25 MAR 2013 Pharmaceuticals
Otsuka Obtains Marketing Approval in Japan for Onglyza® Tablets to Treat Type 2 Diabetes;
Transferred Rights to Kyowa Hakko Kirin
14 MAR 2013 Nutraceuticals
“Weight Management with Chocolate”
White Chocolate and Orange Chocolate
Gerlinea Meal Replacement Bars Debut on March 18
13 MAR 2013 Nutraceuticals
The Healthy Benefits of Whole Soy Flavored with Crunchy Peanuts
SOYJOY Peanuts Debuts April 24
7 MAR 2013 Pharmaceuticals
Otsuka Advancing Rapidly in Central Nervous System Disorders; Expanding Its Existing Collaboration with Lundbeck
1 MAR 2013 Pharmaceuticals
FDA Approves Once-Monthly ABILIFY MAINTENA™ (Aripiprazole) For Extended-Release Injectable Suspension for the Treatment of Schizophrenia
22 FEB 2013 Pharmaceuticals
The First Transdermal Dopamin Agonist in Japan Neupro® Patch, For Both Parkinson’s Disease and Restless Legs Syndrome, To Be Launched on February 26
22 FEB 2013 Pharmaceuticals
L-Cartin® FF oral solution 10% and L-Cartin® FF injection 1000mg
Two New Drug Forms for Carnitine Deficiency To Be Launched on February 26

Go to the Top